New trial puts mirikizumab Head-to-Head with standard Crohn's therapy
NCT ID NCT07659353
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares early treatment with mirikizumab (a biologic drug) to standard therapy with azathioprine plus steroids in 320 adults newly diagnosed with moderate-to-severe Crohn's disease. Participants are randomly assigned to one of two groups for 52 weeks. The goal is to see if starting with mirikizumab leads to better deep remission—meaning no symptoms, healed gut lining, and no need for steroids or surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mirikizumab
- What this could lead to
- If successful, this could show that starting with mirikizumab is more effective than standard therapy for controlling Crohn's disease early on.
- What could go wrong
- This is a Phase 4 trial, but results may not apply to all patients. Mirikizumab can cause side effects like infections or allergic reactions, and the study is open-label, which may bias results.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Schleswig-Holstein
Kiel, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.